Vir Biotechnology said monthly injections of two investigational medicines reduced hepatitis D virus levels to undetectable in 44% of patients receiving the regimen, compared with none in the delayed-treatment group, meeting the Phase 3 study’s primary goal. The result strengthens the case for a time-limited or maintenance-style approach for HDV, a disease with limited therapeutic options. If confirmed in subsequent reporting, the regimen could shift HDV treatment paradigms from supportive care and non-curative strategies toward measurable virologic suppression, potentially improving downstream liver outcomes and transplant needs.